Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
तुलना करने के लिए मीट्रिक्स | 0A8U | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध0A8Uपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.3x | −0.7x | −0.6x | |
PEG अनुपात | 0.00 | −0.02 | 0.00 | |
क़ीमत/बुक | 1.0x | 2.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 5.2x | 2.1x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 149.0% | 57.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 32.5% | 7.3% | अनलॉक करें |